Skip to main content
Fig. 4 | Alzheimer's Research & Therapy

Fig. 4

From: The autocrine motility factor receptor delays the pathological progression of Alzheimer’s disease via regulating the ubiquitination-mediated degradation of APP

Fig. 4

Effects of AMFR on APP amyloidogenic cleavage products. A AMFR and APP protein levels in SH-SY5Y-hAPP cells transfected with empty vector or His-AMFR. Data are shown as mean ± SEM from three independent experiments (*P < 0.05, ****P < 0.0001). B-D sAPPβ, Aβ40, and Aβ42 levels in SH-SY5Y-hAPP cells transfected with empty vector or His-AMFR by ELISA assays. Data are shown as mean ± SEM from three independent experiments (*P < 0.05, ****P < 0.0001). E AMFR and APP protein levels in SH-SY5Y-hAPP cells transfected with siRNA-control or siRNA-AMFR. Data are shown as mean ± SEM from three independent experiments (*P < 0.05, ***P < 0.001). F–H sAPPβ, Aβ40, and Aβ42 levels in SH-SY5Y-hAPP cells transfected with siRNA-control or siRNA-AMFR by ELISA assays. Data are shown as mean ± SEM from three independent experiments (*P < 0.05). I AMFR and APP protein levels in primary neurons of APP/PS1 embryonic mice transfected with empty vector or His-AMFR. Data are shown as mean ± SEM from three independent experiments (*P < 0.05). J-L sAPPβ, Aβ40, and Aβ42 levels in primary neurons of APP/PS1 embryonic mice transfected with empty vector or His-AMFR by ELISA assays. Data are shown as mean ± SEM from three independent experiments (*P < 0.05)

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193